ENLVNasdaqFinance ServicesFiscal year ends December 31
Enlivex Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 25, 2026
$0.21+0.00 (+1.17%)
Close on Oct 19, 2026
- Market cap
- $4.01M
- P/E (TTM)
- 0.0
- Dividend yield
- –
Ownership
Who owns Enlivex's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 2,208,000 | 9.75% | 13G (passive) amendment | Dec 31, 2024 |
| Lind Partners LLC | 1,927,744 | 9.99% | 13G (passive) | Aug 11, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Einat Galamidi | Chief Medical Officer | 156,304 | 0.07% | Mar 18, 2026 |
| Oren Hershkovitz | Chief Executive Officer | 172,855 | 0.07% | Mar 18, 2026 |
| Shachar Shlosberger | Chief Financial Officer | 139,314 | 0.06% | Mar 18, 2026 |
| Shai A. Novik | Director | 6,974,017 | 2.94% | Mar 18, 2026 |
| Avraham Havron | Director | 183,836 | 0.08% | Mar 18, 2026 |
| Gili Hart | Director | 7,672 | 0.00% | Mar 18, 2026 |
| Roger Pomerantz | Director | 2,480 | 0.00% | Mar 18, 2026 |